| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H12N2O3 |
| Molecular Weight | 160.1711 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCO\C=C\[C@H](N)C(O)=O
InChI
InChIKey=USGUVNUTPWXWBA-JRIXXDKMSA-N
InChI=1S/C6H12N2O3/c7-2-4-11-3-1-5(8)6(9)10/h1,3,5H,2,4,7-8H2,(H,9,10)/b3-1+/t5-/m0/s1
| Molecular Formula | C6H12N2O3 |
| Molecular Weight | 160.1711 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Aminoethoxyvinylglycine (Aviglycine, AVG) is a plant regulator used on
apples, pears, and ornamentals. In apples, it may delay fruit maturity, leading to
benefits such as a reduction in pre-harvest fruit drop and improved fruit quality. In
pears, AVG may help maintain fruit firmness. For specific ornamentals (miniature
carnations, hibiscus, and rooted geranium cuttings and seedlings), AVG may
reduce problems, such as flower senescence and flower bud abscission, that occur
during shipping. AVG to be used as a spray solution, applied to apples or pears as a
single application 28 days prior to the anticipated beginning of the normal harvest
period, and to specified ornamentals 24-to -48 hours prior to boxing/shipping.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 10.5 µM [Ki] | |||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
Following a single oral dose of 2.25 or 50 mg/kg bw of 14C-AVG to rats, absorption was
rapid and extensive, although not complete (over 80% of the administered dose), and
excretion was prolonged over many days. The primary route of excretion was via the urine
(approximately 57 to 74%) with faecal excretion a minor route (11.4 to 13.6%). Elimination
in expired air was substantial at a dose of 2.25 mg/kg bw (18 to 22%) but much less
significant at 50 mg/kg bw (4.8%). AVG was not a teratogen when administered to pregnant rats during the period of foetal
organ formation at oral doses of 0, 0.5, 2.2 or 10 mg/kg bw/day.
Route of Administration:
Oral